Literature DB >> 3898350

Parietal cell vagotomy or cimetidine maintenance therapy for duodenal ulcer? A prospective controlled trial.

H Harling, I Balslev, E Bentzen.   

Abstract

In a prospective controlled trial 86 duodenal ulcer patients with symptoms severe enough to indicate surgery were randomized to a full-dose cimetidine course followed by maintenance therapy for 1 year or parietal cell vagotomy (PCV). The average follow-up period was 57 months. In the group assigned to medical therapy 62% of the patients were free of symptoms during maintenance therapy, and 12% remained well during the follow-up period. Operation was later performed in 35%, whereas 53% had symptomatic recurrence demanding medical treatment regularly. After PCV no patient died, and there were no serious sequelae. The overall recurrence rate was 17%; after treatment of failures 9% continued to have dyspepsia. Since nearly 3/4 of the patients were free of symptoms after PCV, operation seems to be the method of choice in patients with a severe history and fast recurrence after medical therapy. However, the aged and those at high risk of surgery may benefit from cimetidine maintenance therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898350     DOI: 10.3109/00365528509089206

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

Review 1.  Long term treatment of duodenal ulcer. A review of management options.

Authors:  G Bianchi Porro; F Parente
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

2.  Should it be parietal cell vagotomy or selective vagotomy-antrectomy for treatment of duodenal ulcer? A progress report.

Authors:  P H Jordan; J Thornby
Journal:  Ann Surg       Date:  1987-05       Impact factor: 12.969

Review 3.  Medical versus surgical treatment for refractory or recurrent peptic ulcer.

Authors:  Kurinchi Selvan Gurusamy; Elena Pallari
Journal:  Cochrane Database Syst Rev       Date:  2016-03-29

4.  [Initial interventions in ulcer disease: indications--choice of procedure--results].

Authors:  W Peitsch
Journal:  Langenbecks Arch Chir       Date:  1987

Review 5.  Current status of proximal gastric vagotomy.

Authors:  B D Schirmer
Journal:  Ann Surg       Date:  1989-02       Impact factor: 12.969

Review 6.  Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  D M Campoli-Richards; S P Clissold
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.